Hyun Wook Kim
PartnerIntroduction
Mr. Hyun Wook Kim is a partner at Shin & Kim. Mr. Kim's practice focuses on advice and resolving disputes related to pharmaceutical, medical, bio and healthcare.
Mr. Kim worked at the Health Insurance Review & Assessment Service (HIRA), the public organization for national healthcare. Mr. Kim has a wide range of work experience in pharmaceutical, medical and health care including pharmaceutical pricing and reimbursement policies in Korea.
Mr. Kim has rich experience in handling response to various regulations related to pharmaceuticals and medical devices by the Ministry of Food and Drug Safety, the Ministry of Health and Welfare, the Health Insurance Review and Assessment Service, and the National Health Insurance Service and in particular, he shows differentiated performance and competence in consulting and litigation on the determination and adjustment of the upper limit amount of health insurance drugs and therapeutic materials. In addition, he has the capacity to respond to all processes from investigation to disposition regarding various sanctions against medical personnel and medical institutions, and has a wide range of litigation and advisory experience regarding regulations on food, health functional foods, quasi-drugs, etc.
Areas of Expertise
Professional Career
- 2024-PresentMember, Institutional Review Board (IRB) of Korea Disease Control and Prevention Agency
- 2018-PresentLecturer, Korea Pharmaceutical Traders Association
- 2017-PresentShin & Kim LLC
- 2015-PresentMember, Institutional Review Board (IRB) of Samsung Medical Center
- 2015-PresentResearcher, Healthcare, Legal and Policy Center of Korea University
- 2012-2017Legal Dept. & Strategy Dept., Health Insurance Review & Assessment Service (HIRA)
- 2006-2009Investigation Dept. & Legal Dept., Health Insurance Review & Assessment Service (HIRA)
Key Experience
- Represented pharmaceutical companies and won multiple administrative litigations against the Minister of Health and Welfare regarding the disposition of drug price reduction
- Represented pharmaceutical companies and won multiple administrative litigations against the Commissioner of the Korea Food and Drug Administration for the suspension of various business operations
- Advised on health insurance registration of new drugs developed by major pharmaceutical companies
- Advised on registration of health insurance for treatment materials developed by major medical device companies
Education
- 2019Korea University School of Public Health (KSPH) Academy
- 2018Korea University Graduate School of Law (Ph.D. Candidate)
- 2018KAIST Advanced Bio Health Innovation Program
- 2012Chung-Ang University School of Law (J.D.)
- 2004Korea University College of Law (LL.B.)
Bar Admissions
- 2012Admitted to bar, Korea
Memberships
- Korean Bar Association
Languages
Korean, English
Professional Activities
- Asia Business Law Journal – A comparison of healthtech regulatory issues in North Asia: Korea (February 2024)
- A Study on the Improvement of Investigation for Healthcare Fraud (Co-researchers, HIRA, 2016)
- A Study on the Regional Management Methods for Cardiocerebrovascular Disease (Co-researchers, HIRA, 2015)
- Legal Issues and Aspects of healthcare cooperation between Medical Institutions (HIRA Policy Brief, 9(1), 2015)
- Intellectual Property Law (Co-authored, Jinwonsa, 2012)
Awards
- 2024Korea Pharmaceutical Traders Association’s Award
- 2015Minister of Health and Welfare’s Award